These Products are useful in removing the metabolites created by use of this drug from your body for a specific period of time. and could be used to help detoxify the body in a shorter period of time that might happen should the body be let to detoxify naturally.  ATC does not condone the use of these products for any purposes that can be illegal in certain areas such as reducing the chance of failing a drug test.

Barbiturates were first introduced for medical use in the early 1900s. More than 2,500 barbiturates have been synthesized, and at the height of their popularity, about 50 were marketed for human use. Today, about a dozen are in medical use. Barbiturates produce a wide spectrum of central nervous system depression, from mild sedation to coma, and have been used as sedatives, hypnotics, anesthetics, and anticonvulsants. The primary differences among many of these products are how fast they produce an effect and how long those effects last. Barbiturates are classified as ultrashort, short, intermediate, and long-acting.

The ultrashort-acting barbiturates produce anesthesia within about one minute after intravenous administration. Those in current medical use are the Schedule IV drug methohexital (Brevital®), and the Schedule III drugs thiamyl (Surital®) and thiopental (Pentothal®). Barbiturate abusers prefer the Schedule II short-acting and intermediate-acting barbiturates that include amobarbital (Amyta®), pentobarbital (Nembutal®), secobarbital (Seconal®), and Tuinal (an amobarbital/secobarbital combination product). Other short and intermediate-acting barbiturates are in Schedule III and include butalbital (Fiorina®), butabarbital (Butisol®), talbutal (Lotusate®), and aprobarbital (Alurate®). After oral administration, the onset of action is from 15 to 40 minutes, and the effects last up to six hours. These drugs are primarily used for insomnia and preoperative sedation. Veterinarians use pentobarbital for anesthesia and euthanasia.

Long-acting barbiturates include phenobarbital (Luminal®) and mephobarbital (Mebaral®), both of which are in Schedule IV. Effects of these drugs are realized in about one hour and last for about 12 hours, and are used primarily for daytime sedation and the treatment of seizure disorders.

Barbiturates have been known since 1864 when Dr. A. von Bayer synthesized barbituric acid. In 1903, barbital was introduced as a hypnotic for routine medicinal use. They were reclassified as Schedule 2 drugs in 1979 requiring a triplicate prescription to reduce the abuse of barbiturates. The benzodiazepines (Valium, Librium, Xanax) are generally safer in overdose and have largely replaced the use of barbiturates in medicinal pharmacology. Barbiturates are numerous, chemically derived from a common 2,4,6 trioxohexahydropyrimidine (barbituric acid) nucleus. Some of the common names are: phenobarbital (Luminol®), secobarbital (Seconal®), pentobarbital (Nembutal®), butalbital (Fiorinal®), amobarbital (Amytal®), and many others.

Pharmacological Effects

Barbiturates reversibly depress the activity of all excitable tissues. The use of phenobarbital in epilepsy, one of the few major remaining useful areas of barbiturate pharmacology, is due to its selective anticonvulsant activity depressing low frequency electrical activity in the cortex. Tolerance to barbiturates occurs with continued use. At first, a generalized sedative effect gives way to tolerance, especially toward effects on mood, sedation, and hypnosis. Like other central nervous system depressant drugs, barbiturates are abused and some individuals develop a dependence on them. Dependence upon and tolerance to barbiturates are closely related. The former, generating the drug seeking behavior that leads to increased usage and consequent higher levels of tolerance and hence the extent, duration, and continuity of abuse prior to withdrawal.

Laboratory Methods

POISONLAB utilizes immunoassay (EIA) for detecting barbiturates in urine. The immunoassays provide a cost effective, sensitive method for detection and reacts with a number of barbiturates. Gas chromatography/mass spectrometry (GC/MS) is used to further identify and confirm the presence of a particular barbiturate in the sample.

Cutoff and Detection Post Dose

The 200 ng/ml cutoff for the screening immunoassay allows detection of barbiturate use for up to 72 hours post dose. The cutoff level for GC/MS is 200 ng/ml for all barbiturate metabolites (amobarbital, butabarbital, butalbital, pentobarbital, phenobarbital, secobarbital). Various barbiturates have differing half lives of clearance post dose. For instance, the short acting barbiturate, secobarbital, has a half life of 29-34 hours, whil phenobarbital, a long acting barbiturate, has a half life of 24-140 hours. Thus, use of phenobarbital may be detected much longer than secobarbital.

How To Pass A Drug Urine Test For Barbiturates.  Learn Detection Times and Cut Off Levels:

• How long the drugs will be detectable depends on which resource you consult.  We have provided a list of conservative Drug Detection Times provided by the manufactures of the drug tests.

• For the cutoff levels of commonly abused drugs and more about drug testing take a look at Drug Testing Cutoff Levels.